Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- OPTN
- Price
- 9.05
- Stock movement down
- -0.05 (-0.55%)
- Company name
- OptiNose
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 91.00M
- Ent value
- 180.62M
- Price/Sales
- 1.20
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -34.78%
- 1 year return
- -54.29%
- 3 year return
- -38.94%
- 5 year return
- -32.13%
- 10 year return
- -
Last updated: 2025-04-09
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OPTN does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 1.20 |
| Price to Book | - |
| EV to Sales | 2.39 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 10.06M |
| EPS (TTM) | -2.68 |
| FCF per share (TTM) | -3.42 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 75.67M |
| Gross profit (TTM) | 68.06M |
| Operating income (TTM) | -19.19M |
| Net income (TTM) | -31.15M |
| EPS (TTM) | -2.68 |
| EPS (1y forward) | -1.45 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.94% |
| Operating margin (TTM) | -25.36% |
| Profit margin (TTM) | -41.16% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 82.50M |
| Net receivables | 29.77M |
| Total current assets | 128.22M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 131.02M |
| Accounts payable | 3.78M |
| Short/Current long term debt | 126.99M |
| Total current liabilities | 162.43M |
| Total liabilities | 172.12M |
| Shareholder's equity | -41.10M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -39.64M |
| Capital expenditures (TTM) | 145.00K |
| Free cash flow (TTM) | -39.79M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -23.77% |
| Return on Invested Capital | -36.26% |
| Cash Return on Invested Capital | -46.32% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 9.14 |
| Daily high | 9.15 |
| Daily low | 9.03 |
| Daily Volume | 107K |
| All-time high | 446.40 |
| 1y analyst estimate | 45.00 |
| Beta | -0.07 |
| EPS (TTM) | -2.68 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| OPTN | S&P500 | |
| Current price drop from All-time high | -97.97% | -19.00% |
| Highest price drop | -98.88% | -56.47% |
| Date of highest drop | 14 Jan 2025 | 9 Mar 2009 |
| Avg drop from high | -78.40% | -11.07% |
| Avg time to new high | 105 days | 12 days |
| Max time to new high | 1698 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
91.00M
Marketcap category
Small-cap
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Employees
132
Website
Investor relations
-
SEC filings
CEO
Peter Kaighn Miller
Country
USA
City
Yardley
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page